Nektar Therapeutics - Company Profile
Powered by 
All the data and insights you need on Nektar Therapeutics in one report.
$295
- Save hours of research time and resources with
our up-to-date Nektar Therapeutics Strategy Report
- Understand Nektar Therapeutics position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Nektar Therapeutics (Nektar) is a pharmaceutical company that discovers and develops novel therapeutic drugs in the field of immunotherapy. Its drug candidates are based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
455 Mission Bay Boulevard South, San Francisco, California, 94158
Website
www.nektar.com
Telephone
1 415 4825300
No of Employees
137
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NKTR (NASD)
Revenue (2022)
$90.1M
-2.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
25%
(2022 vs 2021)
Market Cap*
$306.6M
Net Profit Margin (2022)
XYZ
23.4%
(2022 vs 2021)
* As of and is in US$
Nektar Therapeutics premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Movantik | - |
| Cimzia | Movantik |
| Mircera | Moventig |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into a collaboration with Cellular Biomedicine Group to evaluate the company's NKTR-255, a novel interleukin-15 receptor agonist in combination with CBMG's C-TIL051. |
| 2023 | Others | In February, the company announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of rezpegaldesleukin in adults with moderately-to-severely active systemic lupus erythematosus. |
| 2022 | Others | In October, the company terminated the agreement to merge with PureTech Health. |
Competitor Comparison
| Key Parameters | Nektar Therapeutics | Novo Nordisk AS | Biogen Inc | Dr. Reddy's Laboratories Ltd | NOF Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | Denmark | United States of America | India | Japan |
| City | San Francisco | Bagsvaerd | Cambridge | Hyderabad | Shibuya-Ku |
| State/Province | California | - | Massachusetts | Telangana | Tokyo |
| No. of Employees | 137 | 63,370 | 7,570 | 24,832 | 3,818 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert B. Chess | Chairman | Executive Board | 2007 | - |
| Howard W. Robin | Director; Chief Executive Officer; President | Executive Board | 2007 | 70 |
| Sandra Gardiner | Chief Financial Officer | Senior Management | 2023 | - |
| Mark A. Wilson | Chief Legal Officer; Senior Vice President | Senior Management | 2022 | 51 |
| Mary Tagliaferri, M.D. | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward